1
|
Heidebrecht HJ, Kruse ML, Janßen O, Parwaresch R. Cancer/testis antigen 45 is expressed in a nuclear speckles-like pattern in human tumor cell lines. Cell Commun Signal 2009. [PMCID: PMC4291708 DOI: 10.1186/1478-811x-7-s1-a31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
2
|
Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N. Sequential application of chemotherapy and monoclonal CD 20 antibody: Successful treatment of advanced composite-lymphoma. Leuk Lymphoma 2009; 46:285-8. [PMID: 15621815 DOI: 10.1080/10428190400015535] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We describe successful treatment of a 38-year-old patient with composite lymphoma stage IV(A), who presented with multifocal enlarged lymph nodes. The lymph node histology showed classic morphologic features of Hodgkin's disease, mixed cellularity subtype and follicular B-cell lymphoma. Immunophenotypic analysis showed immunoreactivity for CD20, CD10 and Ki-67 in the malignant small cell population. The areas of Hodgkin's disease demonstrated positive immunoreactivity for CD30 and CD20 in the Hodgkin's cells. Both cell populations were bcl2-oncoprotein positive. Eight courses of dose-escalated BEACOPP were administered. Restaging after chemotherapy showed radiological partial remission, but biopsy confirmed persisting follicular B-cell lymphoma without bone marrow infiltration and no evidence of Hodgkin's disease. He was treated with monoclonal CD 20-antibody (Rituximab) 10 mg/kg weekly for eight consecutive weeks due to marked positivity of CD 20-antigen in follicular lymphoma cells. This treatment was well tolerated and final staging showed complete remission of the composite lymphoma. This patient continues to be in remission 28 months after the end of the treatment. In conclusion, in the very rare case of composite lymphoma a combination of chemotherapy and subsequent immunotherapy might be considered as a promising therapeutic option.
Collapse
Affiliation(s)
- D Linck
- Clinic for BMT and Haematology/Oncology, Germany
| | | | | | | | | | | |
Collapse
|
3
|
|
4
|
Kommoss S, du Bois A, Schmidt D, Parwaresch R, Pfisterer J, Kommoss F. Chemotherapy may be more effective in highly proliferative ovarian carcinomas—A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Gynecol Oncol 2006; 103:67-71. [PMID: 16516280 DOI: 10.1016/j.ygyno.2006.01.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2005] [Revised: 01/04/2006] [Accepted: 01/16/2006] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Proliferative activity (PA) may be an indicator of a neoplasm's malignant potential, and it has been described as a prognostic factor in different malignant tumors. It was our aim to study the prognostic significance of PA defined by Ki-S5 and Ki-S2 immunohistochemical staining in a large homogeneously treated cohort with primary advanced-stage ovarian carcinomas. METHODS Immunohistochemical detection of PA was performed using monoclonal Ki-S5 and Ki-S2 antibodies and standard immunostaining protocols. Kaplan-Meier survival analysis and Cox regression multivariate analysis were performed. RESULTS High Ki-S5 PA was associated with a better prognosis. This finding was statistically significant after univariate and multivariate analysis. A similar trend was found in the subgroup of completely debulked patients. No prognostic effect of Ki-S2 PA could be detected in the present study. CONCLUSION High Ki-S5 PA is an indicator of a more favourable prognosis in patients with advanced ovarian carcinomas. Antiproliferative chemotherapy may be more effective in tumors which are highly proliferative, possibly due to an increased chemosensitivity.
Collapse
|
5
|
Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, Harder L, Schlegelberger B, Mueller F, Harbott J, Reiter A. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 2006; 20:1422-9. [PMID: 16738692 DOI: 10.1038/sj.leu.2404275] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Deletions of chromosome 6q have been reported in several hematological malignancies, but data are not conclusive regarding their biological and prognostic impact. Therefore, we focused on pediatric patients diagnosed with T-cell lymphoblastic lymphoma (T-LBL) treated uniformly according to the NHL-BFM95 protocol. We used loss-of-heterozygosity (LOH) analysis of 25 microsatellite markers located on chromosome 6q14-q24. Fragment-length analysis was performed on ABI-PRISM3100 Genetic-Analyzer. Eligibility criterion was > or =3 informative markers. Between April 1995 and March 2003, 185 T-LBL patients were treated according to the NHL-BFM95 protocol. Five-year event-free (EFS) and disease-free survival (DFS) were 79+/-3 and 87+/-3% (median follow-up 4.7 [1.2-10.1] years). Sixty-one patients were evaluable for LOH analysis, including 18 out of 23 patients with relapse. EFS and DFS were 67+/-6 and 69+/-6% for these 61 patients. Testing of 853 markers in the 61 patients identified the presence of LOH in 19 patients (31%): 13 of the 18 relapse patients and five of the 41 in complete remission (odds ratio 18.7, 95% confidence interval 4.7-75.3). One LOH-positive patient died from treatment-related toxicity. We conclude that LOH on chromosome 6q14-q24 may have conferred a high risk of relapse on our group of children with T-LBL treated according to the NHL-BFM95 protocol.
Collapse
Affiliation(s)
- B Burkhardt
- Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol 2006; 209:250-7. [PMID: 16508921 DOI: 10.1002/path.1961] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Mantle cell lymphoma (MCL) is an IgM-expressing B cell lymphoma that originates from naive B cells and responds poorly to chemotherapy. We show here that several MCLs harbour isotype-switched subclones. Similar to the situation in normal B cells, in vitro stimulation of MCL cell lines with CD40 ligand (CD40L) and interleukin-4 induced expression of activation-induced cytidine deaminase (AID) and germline transcription at the immunoglobulin heavy chain gene locus. Additionally, the occurrence of switch-circle transcripts and mature IgG transcripts after stimulation indicated ongoing class-switch recombination in mantle cell lymphoma cell lines. Furthermore, stimulation of primary MCL cells in vitro induced expression of class-switched IgG mRNA in the tumour cells. Our data indicate that mantle cell lymphomas have retained the ability to undergo class-switch recombination if appropriate stimuli, such as the CD40 ligand, are provided.
Collapse
MESH Headings
- CD40 Antigens/immunology
- Cell Line, Tumor
- Cytidine Deaminase/immunology
- Dendritic Cells, Follicular/immunology
- Genes, Immunoglobulin Heavy Chain/genetics
- Genes, Immunoglobulin Heavy Chain/immunology
- Humans
- Immunoglobulin Class Switching/genetics
- Immunoglobulin Class Switching/immunology
- Immunoglobulin G/genetics
- Immunoglobulin G/immunology
- Immunohistochemistry/methods
- Interleukin-4/immunology
- Lymphoma, Mantle-Cell/genetics
- Lymphoma, Mantle-Cell/immunology
- Mutation/genetics
- Mutation/immunology
- RNA, Messenger/analysis
- RNA, Neoplasm/analysis
- Recombination, Genetic/genetics
- Recombination, Genetic/immunology
- Reverse Transcriptase Polymerase Chain Reaction/methods
- Transcription, Genetic/genetics
- Transcription, Genetic/immunology
Collapse
Affiliation(s)
- W Klapper
- Department of Haematopathology and Lymph Node Registry Kiel, Schleswig-Holstein University Hospitals, Campus Kiel, Niemannsweg 11, 24105 Kiel, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G, Kneba M, Tiemann M, Parwaresch R. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer 2005; 93:939-45. [PMID: 16189522 PMCID: PMC2361659 DOI: 10.1038/sj.bjc.6602795] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Minichromosome maintenance protein 6 (MCM6) is one of six proteins of the MCM family which are involved in the initiation of DNA replication and thus represent a marker of proliferating cells. Since the level of cell proliferation is the most valuable predictor of survival in mantle cell lymphoma (MCL), we investigated lymph node biopsy specimens from 70 patients immunohistochemically with a monoclonal antibody against MCM6. The percentage of MCM6 expressing lymphoma cells ranged from 12.0 to 95.6%, with a mean of 61.0%, and was significantly higher than the percentage of Ki-67-positive cells (P<0.0001). Surprisingly, the ratio of MCM6-positive cells to Ki-67-positive cells was higher than in normal stimulated peripheral blood mononuclear cells, indicating a cell early G1-phase arrest in MCL. A high MCM6 expression level of more than 75% positive cells was associated with a significantly shorter overall survival time (16 months) compared to MCL with a low MCM6 expression level of less than 25% (no median reached, P<0.0001). Multivariate analysis revealed MCM6 to be an independent predictor of survival that is superior to the international prognostic factor and the Ki-67 index. Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL.
Collapse
Affiliation(s)
- C Schrader
- Second Department of Internal Medicine and Hematology, University Hospital of Schleswig-Holstein, Campus Kiel, Chemnitzstr. 33, 24116 Kiel, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Arland M, Nebe T, Parwaresch R, Tiemann M, Ranze O, Krüger WH, Höffkes HG. Transient clonal expansion of large granular lymphocytes in a patient with LGL syndrome. Ann Hematol 2005; 85:60-2. [PMID: 16175351 DOI: 10.1007/s00277-005-1100-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2005] [Accepted: 05/30/2005] [Indexed: 10/25/2022]
|
9
|
Gesk S, Gascoyne RD, Schnitzer B, Bakshi N, Janssen D, Klapper W, Martín-Subero JI, Parwaresch R, Siebert R. ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia 2005; 19:1839-40. [PMID: 16107887 DOI: 10.1038/sj.leu.2403921] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
10
|
Murga Penas EM, Lampe W, Hinz K, Zivković T, Röser K, Copie-Bergmann C, Gaulard P, Löning T, Parwaresch R, Hossfeld DK, Dierlamm J. MLT/MALT1 involving translocations and amplifications are important mechanisms in the pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. M. Murga Penas
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - W. Lampe
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - K. Hinz
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - T. Zivković
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - K. Röser
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - C. Copie-Bergmann
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - P. Gaulard
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - T. Löning
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - R. Parwaresch
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - D. K. Hossfeld
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| | - J. Dierlamm
- Univ Hosp Hamburg-Eppendorf, Hamburg, Germany; Hosp Henri Mondor, Créteil, France; Univ of Kiel, Kiel, Germany
| |
Collapse
|
11
|
Hoffmann C, Schrader C, Janssen D, Wolf E, Parwaresch R, Vierbuchen M, Ernestus K, Horst HA, Fatkenheuer G, Tiemann M. AIDS-related B-cell lymphoma: Outcome correlates with differentiation profiles assessed by immunophenotyping. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Hoffmann
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - C. Schrader
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - D. Janssen
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - E. Wolf
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - R. Parwaresch
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - M. Vierbuchen
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - K. Ernestus
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - H.-A. Horst
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - G. Fatkenheuer
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| | - M. Tiemann
- Univ of Kiel, Kiel, Germany; Curatorium for Immunodeficiency, Munich, Germany; Hosp St. Georg, Hamburg, Germany; Univ of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Dreyling MH, Forstpointner R, Ludwig WD, Gramatzki M, Boeck HP, Haenel M, Wandt H, Parwaresch R, Unterhalt M, Hiddemann W. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6528] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. H. Dreyling
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - R. Forstpointner
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - W.-D. Ludwig
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Gramatzki
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - H.-P. Boeck
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Haenel
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - H. Wandt
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - R. Parwaresch
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Unterhalt
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - W. Hiddemann
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
13
|
Gockel HR, Heidemann J, Lugering A, Mesters RM, Parwaresch R, Domschke W, Lugering N. Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma. Eur J Haematol 2005; 74:445-7. [PMID: 15813921 DOI: 10.1111/j.1600-0609.2005.00419.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
We describe a case of primary hepatic marginal zone B-cell lymphoma in a 36-year-old Caucasian male with a history of chronic hepatitis B infection. Immunohistochemically, extensive infiltration by a CD20-positive, CD5- negative and CD10-negative lymphoid cell population displaying a follicular arrangement was detected. Molecular analysis of immunoglobulin heavy chain gene rearrangements confirmed the clonal expansion of lymphoma cells. Fourteen months after surgical treatment, the tumour recurred in close proximity to the liver hilus, hampering further surgery. Therefore, we implemented a therapy using the monoclonal anti-CD20-antibody rituximab in a dose of 375 mg/m(2), administered four times once a week. Six, 10, 18, and 26 months later the recurrent lymphoma could no longer be detected as shown by abdominal ultrasonography and CT. This case report demonstrates the difficulties of treating this extremely rare liver disease and shows its response to rituximab therapy.
Collapse
Affiliation(s)
- H R Gockel
- Department of Medicine B, University of Muenster, Muenster, Germany.
| | | | | | | | | | | | | |
Collapse
|
14
|
Klapper W, Moosig F, Sotnikova A, Qian W, Schröder JO, Parwaresch R. Telomerase activity in B and T lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63:1681-3. [PMID: 15547095 PMCID: PMC1754866 DOI: 10.1136/ard.2003.016022] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To evaluate telomerase activity as a marker of lymphocyte proliferation in systemic lupus erythematosus (SLE). METHODS CD19+, CD4+, and CD8+ lymphocytes were isolated from the peripheral blood of nine patients with SLE and nine healthy controls by means of magnetic bead-coupled antibodies and tested for telomerase activity with the TRAP assay. RESULTS Telomerase activity was significantly increased in CD19+ B cells from patients with SLE. CD4+ and CD8+ T cells from lupus patients displayed increased mean telomerase activity, although the difference from normal controls did not reach statistical significance. CONCLUSIONS Increased telomerase activity in the B and the T cell lineage might indicate activation and proliferation of these lymphocytes.
Collapse
Affiliation(s)
- W Klapper
- Department of Haematopathology and Lymph Node Registry Kiel, University Kiel, Germany.
| | | | | | | | | | | |
Collapse
|
15
|
Hiddemann W, Dreyling M, Unterhalt M, Repp R, Hermann S, Haenel A, Metzner B, Pott C, Hartmann F, Parwaresch R. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - M. Dreyling
- Ludwig-Maximilians-University, München, Germany
| | | | - R. Repp
- Ludwig-Maximilians-University, München, Germany
| | - S. Hermann
- Ludwig-Maximilians-University, München, Germany
| | - A. Haenel
- Ludwig-Maximilians-University, München, Germany
| | - B. Metzner
- Ludwig-Maximilians-University, München, Germany
| | - C. Pott
- Ludwig-Maximilians-University, München, Germany
| | - F. Hartmann
- Ludwig-Maximilians-University, München, Germany
| | | |
Collapse
|
16
|
Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D, Parwaresch R, Tiemann M. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004; 18:1200-6. [PMID: 15116121 DOI: 10.1038/sj.leu.2403387] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Mantle cell lymphoma (MCL) is a malignant lymphoma associated with a relatively aggressive clinical course and a median overall survival time of 3-4 years. Treatment usually consists of combination chemotherapy, often including topoisomerase (topo) inhibitors such as doxorubicin, etoposide and mitoxantrone. Topo IIalpha is an enzyme that is needed whenever uncoiling of DNA is necessary during the cell cycle. The enzyme is a marker of cell proliferation. We analyzed the expression of topo IIalpha in relation to Ki-67 and the clinical outcome in patients with MCL. Biopsy specimens from 95 untreated patients enrolled in two multicenter trials (1975-1985) were investigated immunohistochemically with monoclonal antibodies against topo IIalpha (Ki-S4) and Ki-67 (Ki-S5). Patients with low (0-10%) topo IIalpha expression had a median overall survival time of 49.0 months, compared to 17.0 months for patients with high (more than 10%) topo IIalpha expression. The Kaplan-Meier analysis showed a significant difference in the overall survival time related to the percentage of topo IIalpha (P<0.001) and Ki-67 (P<0.001) positive tumor cells. Multivariate Cox regression analysis revealed the expression of topo IIalpha as the most important prognostic factor (P<0.001) in MCL superior to the international prognostic index (IPI), the Ki-67 index and other clinical characteristics.
Collapse
Affiliation(s)
- C Schrader
- II. Department of Internal Medicine and Hematology, University Hospital of Schleswig-Holstein, Kiel, Germany
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Kuropkat C, Rudolph P, Dünne AA, Parwaresch R, Werner JA. Der Proliferationsmarker Ki-S1 im Tiermodell als potentielle Entscheidungshilfe zur Indikation einer Chemotherapie. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Schrader C, Janssen D, Kneba M, Meusers P, Brittinger G, Parwaresch R, Tiemann M. Minichromosome maintenance protein 6 (MCM6) in mantle cell lymphoma: a clinicopathological study of 70 patients. Pathol Res Pract 2004. [DOI: 10.1016/s0344-0338(04)80729-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Frahm S, Rudolph P, Tiemann M, Parwaresch R. Diffuse large B-cell lymphoma of the skin — Analysis of histolgy, antigen profile and clinical correlation. Pathol Res Pract 2004. [DOI: 10.1016/s0344-0338(04)80733-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Schrader C, Janssen D, Siebert R, Harder L, Tiemann M, Parwaresch R, Kneba M, Pott C. Immunohistochemical detection of ZAP70 in mantle cell lymphoma does not correlate with immunoglobulin heavy-chain variable-region mutation status. Pathol Res Pract 2004. [DOI: 10.1016/s0344-0338(04)80523-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Abstract
Primary manifestation of malignant lymphoma and/or leukaemia rarely occurs in the kidney. It can be the cause of a hitherto unexplained acute renal failure or it is incidentally detected as shown in the three cases under report.1.A 68-year-old man was operated on because of a symptomatic tumour in his right kidney. At nephrectomy, a conventional (clear cell) renal cell carcinoma was found simultaneously with an occult mantle cell lymphoma infiltrating the adjacent renal and extrarenal tissue. Clinical follow-up uncovered nodal and bone marrow involvement, so that a primary renal manifestation of mantle cell lymphoma was apparent.2.A 69-year-old man with suspected vertebral metastasis underwent partial renal resection because of a mass in his left kidney. Histologically and immunohistochemically, the renal infiltration was diagnosed as a precursor B-lymphoblastic lymphoma. After chemotherapy and irradiation, leukaemic blood cell counts with 50% lymphoblasts proved a primary renal manifestation of precursor B-lymphoblastic leukaemia/lymphoma.3.A 13-year-old boy presented clinically with renal failure, enlarged kidneys, and normal urinalysis. Renal biopsy showed a diffuse interstitial infiltration with atypical T-lymphoblasts compressing tubules and surrounding preserved glomeruli. Subsequent clinical bone marrow smears presented 60% T-lymphoblasts, so that the final diagnosis of a primary renal manifestation of acute T-lymphoblastic leukaemia of mature thymic cortex type was made. Immediate chemotherapy resulted in total recovery of renal function and bone marrow findings.
Collapse
Affiliation(s)
- H Nizze
- Institut für Pathologie der Universität Rostock.
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
Telomerase activity transiently increases when HL60 cells are treated with the topoisomerase II inhibitor etoposide. A quantitative assessment revealed that telomerase is activated by etoposide treatment in a number of cell lines and that the increase is reversible after withdrawal of etoposide from the cell culture. Telomerase activation correlated with the occurrence of DNA damage but not with cell cycle arrest. We did not detect any transcriptional upregulation of hTERT mRNA, suggesting a post-transcriptional mechanism of telomerase activation. Furthermore, the mRNA expression of the telomere binding protein TRF2 was upregulated early and reversibly after etoposide treatment. TRF1 mRNA expression levels were unchanged after DNA damage, but increased when the cells accumulated in the G2/M phase. The data show that the telosome reacts after DNA damage by upregulating telomerase activity and TRF2 expression in malignant cells. It has previously been shown that overexpression of TRF2 can repress senescence signals arising from critically shortened telomeres. We show here that TRF2 is upregulated by undirected DNA damage that also affects the telomeric DNA. These data suggest that upregulation of telomerase activity and TRF2 expression might act as antiapoptotic mechanisms in the DNA-damage response of malignant cells.
Collapse
Affiliation(s)
- W Klapper
- Department of Hematopathology and Lymph Node Registry Kiel, Niemannsweg Kiel, Germany
| | | | | | | |
Collapse
|
23
|
Klapper W, Krams M, Qian W, Janssen D, Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer 2003; 89:713-9. [PMID: 12915884 PMCID: PMC2376911 DOI: 10.1038/sj.bjc.6601112] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Telomere maintenance is a prerequisite for immortalisation, and in most malignant cells is carried out by telomerase, an enzyme that synthesis new telomeric repeats on the chromosome ends. In normal or reactive tissues with a high regenerative capacity, telomerase is regulated according to the telomere loss that occurs during proliferation. To evaluate the interaction of proliferation and telomerase activity in malignant lymphomas, we quantified telomerase expression in different non-Hodgkin lymphomas in comparison to normal or reactive lymph nodes. Surprisingly, the activity levels were the same in most of the lymphomas analysed as compared to reactive lymph nodes. Significantly higher activity was detected only in Burkitt's lymphoma. Telomerase activity correlated well with hTERT and c-myc expression, but was independent of proliferation. To evaluate interactions of telomere-binding protein expression on telomerase expression in non-Hodgkin lymphoma, the mRNA levels of TRF1, TRF2, tankyrase and hPif1 were assessed by real-time RT-PCR. We demonstrate here that the magnitude of telomerase upregulation does not necessarily reflect the requirement of telomere compensation caused by proliferation. Telomerase regulation in non-Hodgkin lymphomas is therefore uncoupled from proliferative stimuli found in reactive lymphoid tissue. We suggest that the upregulation of specific telomere-binding proteins like TRF2 may contribute to telomere maintenance in malignant lymphoma.
Collapse
Affiliation(s)
- W Klapper
- Institute of Hematopathology and Lymph Node Registry Kiel, Niemannsweg 11, 24105 Kiel, Germany.
| | | | | | | | | |
Collapse
|
24
|
Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol 2003; 21:1782-9. [PMID: 12721255 DOI: 10.1200/jco.2003.08.151] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin's lymphoma (NHL) arising from thymic mature B cells. Optimal treatment strategies remain to be established, especially in pediatric patients. PATIENTS AND METHODS This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL-Berlin-Frankfurt-Münster Group (BFM) trials. Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin. Radiation was not part of the protocol. RESULTS From April 1986 to August 1999, 1,650 patients with newly diagnosed NHL were enrolled in the NHL-BFM trials; 30 patients (1.8%) had PMLBL. Median age was 14.3 years (range, 1.4 to 16.7 years); 15 patients were male and 15 patients were female. With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08). Two patients erroneously diagnosed as T-cell NHL received non-B-cell therapy and died from progress of disease. Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6). Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy. LDH > or = 500 U/L was associated with increased risk of failure in multivariate analysis. CONCLUSION PMLBL mainly is found in adolescents. Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08). LDH is of prognostic value in pediatric patients with PMLBL.
Collapse
MESH Headings
- Adolescent
- Adrenal Cortex Hormones/therapeutic use
- Antineoplastic Agents, Alkylating/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/analysis
- Child
- Child, Preschool
- Cytarabine/administration & dosage
- Disease Progression
- Disease-Free Survival
- Doxorubicin/administration & dosage
- Etoposide/administration & dosage
- Female
- Follow-Up Studies
- Humans
- Infant
- L-Lactate Dehydrogenase/analysis
- Lymphoma, B-Cell/complications
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Methotrexate/administration & dosage
- Prognosis
- Sclerosis/etiology
- Sclerosis/pathology
- Treatment Outcome
Collapse
Affiliation(s)
- K Seidemann
- Department of Pediatric Hematology and Oncology, Medizinische Hochschule Hannover, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215:139-45. [PMID: 12838937 DOI: 10.1055/s-2003-39372] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND In 5 consecutive pediatric and adolescent Hodgkin's disease trials DAL-HD since 1978 the invasive diagnostic procedures and the radiotherapy have gradually been reduced and chemotherapy modified to minimize toxicity and the risk of late effects. Since 1982 the overall survival increased up to 95%. In this trial the possibility of reducing local radiation doses to 20 Gy in patients with good response to chemotherapy and omitting radiotherapy totally for patients with complete remission after chemotherapy was tested. PATIENTS AND METHODS Over a period of 6 years, from August 1995 to July 2001, 1018 children and adolescents with Hodgkin's disease from Germany, Austria,Switzerland, the Netherlands, Sweden, Norway and Denmark were enrolled in this trial. The chemotherapy was equivalent to previous trial DAL-HD 90. The treatment group (TG) 1 (stages I and IIA) received 2 cycles OPPA for girls and 2 cycles OEPA for boys, TG2 (stages IIEA, IIB, IIIA) and TG3 (stages IIEB, IIIEA, IIIB, IV) received additional 2 or 4 cycles COPP respectively. In contrast to trial DAL-HD 90 boys in stage IIIB and IIIEB received OPPA instead of OEPA. The initial staging as well as the restaging for evaluating tumor volume reduction after chemotherapy was reviewed by the study center. Radiotherapy was planned accordingly: patients with complete remission after chemotherapy were not irradiated (21.9%); all other patients received local radiotherapy to the initially involved sites, depending on the tu-mor response. Patients with a partial remission of> 75 tumor regression were irradiated with 20 Gy (50AX), partial remission of< 75% with 30 Gy (4.1 %), and residual masses of > 50 ml were boosted up to 35 Gy (20.2 %). RESULTS 36 tumor progressions and 49 relapses occurred over a period of 7 1/2 years (median followup 3 years, data deadline 12/19/02). Kaplan-Meier-analysis after 5 years showed a probability for event-free survival (pEFS) for all patients of 0.88 and for overall survival (pOS) of 0.97. For the total group the pDFS (disease free survival) was lower in 222 non irradiated patients than in the 758 irradiated patients (0.88 vs. 0.92,p - 0.049). But there was a difference between the individual treatment groups. In TG 1 there was no difference between nonirradiated and irradiated patients (0.97 vs. 0.94) and the non-ir-radiated patients showed a better trend. In TG 2, and in TG 2 and TG 3 combined, the pDFS was significantly worse for non irradiated patients in comparison with the irradiated patients (TG2:0.78 vs. 0.92; TG 2 +3:0.79 vs. 0.91). Compared to former DAL-HD trials the pOS stayed stable despite therapy reduction. CONCLUSIONS A reduction of radiotherapy to 20 Gy for patients in all stages with good response to chemotherapy is possible without deterioration of the results. The omission of radiotherapy for patients in complete remission after chemotherapy is recommended only for patients in early stages (TG1). In future trials the possibility of a wider selection for chemotherapy alone for this group needs to be evaluated. In intermediate (TG2) and advanced (TG3) stages omission of radiotherapy for patients incomplete remission results in a lower pEFS, but the pOS is not significantly reduced. Only with knowledge of the long term effects of today's therapy we can give a satisfactory answer to the question whether in future trials the primary aim should be pEFS as high as possible due to front-line-therapy or reduction of late effects.
Collapse
Affiliation(s)
- W Dörffel
- Klinik für Kinderheilkunde und Jugenmedizin, Bereich Onkologie/Hämatologie, Helios-Klinikum Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, Parwaresch R, Kneba M, Schmitz N, Haas R. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2002; 1:87-94. [PMID: 11920175 DOI: 10.1038/sj.thj.6200007] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/1999] [Accepted: 09/17/1999] [Indexed: 11/09/2022]
Abstract
INTRODUCTION The purpose of this analysis was to investigate if early sequential high-dose therapy with autologous stem cell transplantation (ASCT) can improve the poor prognosis of patients with disseminated mantle cell lymphoma (MCL). PATIENTS AND METHODS A joint analysis of two parallel single center studies was performed. Both were characterized by a sequential high-dose therapy consisting of an intensive chemotherapy ('HAM' or 'Dexa-BEAM') for mobilization of peripheral blood stem cells and induction of minimal disease followed by a total body irradiation-containing myeloablative regimen and ASCT. Forty-six patients with reference panel-confirmed stage III/IV MCL were included. Thirty-four patients were accrued to the protocol immediately after diagnosis ('upfront ASCT' group). These 34 patients received a standard first-line regimen prior to mobilization. The remaining 12 patients were put on the protocol later during the course of their disease ('delayed ASCT' group). RESULTS All patients were in remission after mobilization chemotherapy and proceeded to ASCT; there were no exclusions due to poor response, poor mobilization, or patient refusal. With a follow-up of 24 (2-73) months post transplant, the event-free and overall survival probabilities at 2 years were 77 and 100% for the upfront ASCT group compared to 30% (P=0.0007) and 54% (P=0.0016) for the delayed ASCT group. Event-free and overall survival tended to be longer in the upfront ASCT group than in the delayed ASCT group also if calculated from initial diagnosis (76 and 93% vs 42 and 63%, respectively, at 4 years after diagnosis; median follow-up 35 months), although this was not statistically significant. Besides timing of ASCT, only spleen size was identified as an independent predictor of survival by univariate and multivariate analysis. CONCLUSION ASCT is not curative but may improve the prognosis of patients with MCL if performed as part of an intensive first-line treatment strategy. In contrast, the benefits of this approach for salvaging individuals with relapsed disease appear to be limited.
Collapse
Affiliation(s)
- P Dreger
- Second Department of Medicine, University of Kiel, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Grenzebach J, Schrappe M, Ludwig WD, Parwaresch R, Zimmermann M, Gadner H, Riehm H, Reiter A. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy. Ann Hematol 2002; 80 Suppl 3:B73-6. [PMID: 11757713 DOI: 10.1007/pl00022795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
In study NHL-BFM 90 we investigated the efficacy of an ALL-type treatment without local radiotherapy for childhood T-cell lymphoblastic lymphoma (T-LBL). In particular, the prognostic impact of the speed of tumor regression was evaluated. From April 1990 to March 1995, 105 evaluable patients, 1.1-16.4 years of age, with T-LBL were enrolled into study NHL-BFM 90. Patients with stage I and II received an 8-drug induction followed by a consolidation including high-dose-methotrexate (MTX) and maintenance therapy up to a total therapy duration of 24 months. Patients with stage III and IV received an additional reinduction and cranial radiotherapy (CRT) (12 Gy for prophylaxis) between consolidation and maintenance. Residual tumor after completion of induction had to be resected. No local RT was applied. Patients received intensified chemotherapy if tumor regression on day 33 of induction was <70% or when vital residual tumor was present after the induction phase. With a median follow-up of 6.41 years, pEFS at 5 years is 91.4% (SE+/-2.7%). 101 patients were evaluable for the speed of tumor response. Two patients received intensified therapy due to <70% tumor regression on day 33. Of 19 patients with tumor residues after induction, 2 relapsed as compared to 4 of 80 patients with complete tumor regression. Our data demonstrate that, with intensive ALL-type chemotherapy but no local radiotherapy, an event-free survival rate of 90% can be achieved in childhood T-LBL. Providing tumor regression within 5 weeks is sufficient, tumor remnants after induction have weak prognostic impact.
Collapse
Affiliation(s)
- J Grenzebach
- Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Willich NA, Reinartz G, Reers B, Hiddemann W, Tiemann M, Parwaresch R, Grothaus-Pinke B, Kocik J, Koch P. Radiotherapy in early stage gastrointestinal lymphoma: results of the German GIT-NHL group. Ann Hematol 2002; 80 Suppl 3:B97-9. [PMID: 11757719 DOI: 10.1007/pl00022801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Combined Modality Therapy
- Cyclophosphamide/administration & dosage
- Disease-Free Survival
- Doxorubicin/administration & dosage
- Gastrectomy
- Gastrointestinal Neoplasms/mortality
- Gastrointestinal Neoplasms/pathology
- Gastrointestinal Neoplasms/radiotherapy
- Gastrointestinal Neoplasms/surgery
- Humans
- Life Tables
- Lymph Node Excision
- Lymphoma, B-Cell, Marginal Zone/mortality
- Lymphoma, B-Cell, Marginal Zone/pathology
- Lymphoma, B-Cell, Marginal Zone/radiotherapy
- Lymphoma, B-Cell, Marginal Zone/surgery
- Lymphoma, Non-Hodgkin/mortality
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/radiotherapy
- Lymphoma, Non-Hodgkin/surgery
- Prednisone/administration & dosage
- Radiotherapy, Adjuvant
- Remission Induction
- Survival Analysis
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- N A Willich
- Department of Radiotherapy, University of Münster, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Parwaresch R, Rudolph P. Leistung und Perspektiven der modernen Pathologie in der Tumordiagnostik. Oncol Res Treat 2002. [DOI: 10.1159/000055247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
30
|
Abstract
Metastasis of thin melanomas is uncommon and unpredictable. We prospectively investigated the clinical course of 167 thin melanomas (<1 mm thickness) over a median observation period of 4 years (18 to 87 months). In addition to Breslow thickness, Clark level, and growth phase characteristics, we assessed cellular proliferation by counting mitoses and immunohistochemically using the monoclonal antibody Ki-S5 (Ki-67). Mitotic and Ki-S5 indices were correlated to tumor thickness, Clarks level, and radial/vertical growth phase (RGP/VGP). However, 5 tumors had proliferation indices above 25% (outside the range of a theoretical normal distribution). Four of these tumors metastasized, and none of the melanomas with lower proliferative activity progressed during the observation period. The metastatic behavior was independent of tumor thickness and Clark level and did not unconditionally coincide with VGP or high mitotic counts. It is concluded that the immunohistochemical proliferation index may be a powerful predictor of early systemic progression in thin melanomas, which may be helpful in making therapeutic decisions. Further investigations are needed to determine the value of proliferation measurements for the long-term prognosis of thin melanomas.
Collapse
Affiliation(s)
- S O Frahm
- Department of Pathology, University of Kiel, Germany
| | | | | | | |
Collapse
|
31
|
Krams M, Claviez A, Heidorn K, Krupp G, Parwaresch R, Harms D, Rudolph P. Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. The American Journal of Pathology 2001; 159:1925-32. [PMID: 11696453 PMCID: PMC1867056 DOI: 10.1016/s0002-9440(10)63039-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
It has been proposed that the regulation of telomerase takes place at the transcriptional level, the expression of the catalytic subunit human telomerase reverse transcriptase (hTERT) being crucial for telomerase activity (TA). Recently, differential splicing of hTERT mRNA has been demonstrated in various tissues during embryonal development, and it has been suggested that only full-length transcripts translate into functionally active telomerase. With this in view, we analyzed the different hTERT transcripts by reverse transcriptase-polymerase chain reaction in neuroblastic tumors and compared the results with the TA, the tumor growth fraction, and the MYCN status. In a series of 38 neuroblastic tumors, high TA and full-length hTERT transcripts were found in nine samples, whereas nine samples showed absence of both enzymatic activity and hTERT transcripts. Interestingly, in another eight samples, low or absent TA coincided with a lack of full-length hTERT transcripts. Eleven samples contained hTERT transcripts with low or undetectable TA and one sample had low TA but no hTERT transcripts. TA correlated with MYCN amplification and was weakly associated with the proliferative activity. Moreover, a significant correlation with tumor progression was observed. Our findings point at a posttranscriptional regulation of TA in a subset of neuroblastic tumors. Because high TA was detected only in tumors with full-length hTERT transcripts, reverse transcriptase-polymerase chain reaction analysis of archival neuroblastic tumor samples might help to appraise the malignant potential in individual cases.
Collapse
Affiliation(s)
- M Krams
- Department of Pathology, University of Kiel, Kiel, Germany.
| | | | | | | | | | | | | |
Collapse
|
32
|
Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3861-73. [PMID: 11559724 DOI: 10.1200/jco.2001.19.18.3861] [Citation(s) in RCA: 349] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
PURPOSE The study was initiated to obtain epidemiologic data and information on anatomic and histologic distribution, clinical features, and treatment results in patients with primary gastrointestinal non-Hodgkin's lymphomas (PGI NHL). PATIENTS AND METHODS Between October 1992 and November 1996, 371 PGI NHL patients were eligible to evaluate clinical features. Radiotherapy and chemotherapy were stratified according to histologic grading, stage, and whether surgery had been carried out or not. RESULTS A total of 74.8% patients had gastric NHL (PGL). Within the intestine, the small bowel and the ileocecal region were involved in 8.6% and 7.0% of the cases, respectively. Multiple GI involvement (MGI) was 6.5%. Approximately 90% of the GI NHL were in stages IE/IIE. Aggressive NHL accounted for the majority, with a distinguishable pattern in several sites. Forty percent of PGL were of low-grade mucosa-associated lymphatic tissue type. One third of large-cell lymphomas had low-grade components. Most intestinal NHL were germinal-center lymphomas. The site of origin was prognostic. In gastric and ileocecal lymphoma, event-free (EFS) and overall survival (OS) were significantly higher as compared with the small intestine or MGI (median time of observation, 51 months). In PGL, localized disease was prognostic for EFS and OS. Histologic grade influenced only EFS significantly. Numbers in intestinal lymphomas were too small for subanalyses. CONCLUSION PGI NHL are heterogeneous diseases. The number of localized PGL allowed for detailed analyses. Larger studies are needed for stages III and IV and for intestinal NHL. A uniform reporting system for PGI NHL, in terms of definitions and histologic and staging classifications, is needed to facilitate comparison of treatment results.
Collapse
Affiliation(s)
- P Koch
- Department of Medicine, Institute for Medical Informatics and Biomathematics, Westfälische-Wilhelms-Universität, Münster, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3874-83. [PMID: 11559725 DOI: 10.1200/jco.2001.19.18.3874] [Citation(s) in RCA: 175] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The aim of the study was to obtain data on anatomic and histologic distribution, clinical features, and treatment results of patients with primary gastrointestinal non-Hodgkin's lymphomas, particularly combined surgical and conservative treatment (CSCT) versus conservative treatment (CT) alone for primary gastric lymphoma (PGL) in localized stages. PATIENTS AND METHODS Whether the treatment included surgery was left to the discretion of each participating center. Radiotherapy (Rx) and chemotherapy were stratified according to histologic grading, stage, and the inclusion or omission of surgery as follows: patients with low-grade PGL were treated with extended-field (EF) Rx (30 Gy). In case of residual tumor after surgery or in case of CT only (in stage IIE after six cycles of cyclophosphamide, vincristine, and prednisone), an additional boost of 10 Gy was given. All patients with high-grade PGL were treated with four (stage IE) or six (stage IIE) cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by EF Rx (stage IE) or involved-field (IF) Rx (stage IIE). Rx dosage corresponded to low-grade NHL. RESULTS Between October 1992 and November 1996, 106 patients had CT only. The survival rate (SR) after 5 years was 84.4% and was influenced neither by patients' characteristics nor by stage or histologic grade. Seventy-nine patients had CSCT. Their SR was 82.0%. Complete resection of the tumor (R0) was prognostic for the overall survival (P =.0165) as compared with incomplete resection. CONCLUSION Although the study was not randomized, a stomach-conserving approach may be favored.
Collapse
Affiliation(s)
- P Koch
- Department of Medicine, and Institute for Medical Informatics and Biomathematics, Westfälische-Wilhelms-Universität, Münster, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Heidebrecht HJ, Buck F, Endl E, Kruse ML, Adam-Klages S, Andersen K, Frahm SO, Schulte C, Wacker HH, Parwaresch R. Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. J Transl Med 2001; 81:1163-5. [PMID: 11502867 DOI: 10.1038/labinvest.3780328] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- H J Heidebrecht
- Department of Hematopathology and Lymph Node Registry, German Association of Pathologists, University of Kiel, Kiel, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, Dörffel W, Zimmermann M, Mann G, Gadner H, Parwaresch R, Riehm H, Reiter A. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001; 97:3699-706. [PMID: 11389005 DOI: 10.1182/blood.v97.12.3699] [Citation(s) in RCA: 199] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Anaplastic large-cell lymphoma (ALCL) accounts for approximately 10% of pediatric non-Hodgkin lymphoma (NHL). Previous experience from NHL-Berlin-Frankfurt-Münster (BFM) trials indicated that the short-pulse B-NHL-type treatment strategy may also be efficacious for ALCL. The purpose of this study was to test the efficacy of this protocol for treatment of childhood ALCL in a large prospective multicenter trial and to define risk factors. From April 1990 to March 1995, 89 patients younger than 18 years of age with newly diagnosed ALCL were enrolled in trial NHL-BFM 90. Immunophenotype was T-cell in 40 patients, B-cell in 5, null in 31, and not determined in 13. Stages were as follows: I, n = 8; II, n = 20; III, n = 55; IV, n = 6. Extranodal manifestations were as follows: mediastinum, n = 28; lung, n = 13; skin, n = 16; soft tissue, n = 13; bone, n = 14; central nervous system, n = 1; bone marrow, n = 5. After a cytoreductive prephase, treatment was stratified into 3 branches: patients in K1 (stage I and II resected) received three 5-day courses (methotrexate [MTX] 0.5 g/m(2), dexamethasone, oxazaphorins, etoposide, cytarabine, doxorubicin, and intrathecal therapy); patients in K2 (stage II nonresected and stage III) received 6 courses; patients in K3 (stage IV or multifocal bone disease) received 6 intensified courses including MTX 5 g/m(2), high-dose cytarabine/etoposide. The Kaplan-Meier estimate for a 5-year event-free survival was 76% +/- 5% (median follow-up, 5.6 years) for all patients and 100%, 73% +/- 6%, and 79% +/- 11% for K1, K2, and K3, respectively. Events were as follows: progression during therapy, n = 2; progression or relapse after therapy, n = 20; second malignancy, n = 1. It was concluded that short-pulse chemotherapy, stratified according to stage, is effective treatment for pediatric ALCL. B symptoms were associated with increased risk of failure. (Blood. 2001;97:3699-3706)
Collapse
Affiliation(s)
- K Seidemann
- Department of Pediatric Hematology and Oncology, Medizinische Hochschule, Hannover, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, Krupp G, Parwaresch R, Rudolph P. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol 2001; 32:605-14. [PMID: 11431715 DOI: 10.1053/hupa.2001.25002] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Telomerase activity, a mechanism granting cellular immortality, has been detected in most cancer entities, but its association with clinical, histopathologic, and prognostic parameters is not fully understood. We investigated whether quantitative telomerase levels are correlated to established prognostic factors, telomere lengths, cell cycle kinetics, and the clinical course in endometrioid adenocarcinoma of the uterus (EC). A modified telomeric repeat amplification protocol (TRAP) was used to quantify the relative telomerase activity in a series of 53 primary tumors. Mean telomere length was determined by Southern blot analysis. Cell cycle kinetics were studied immunohistochemically on paraffin sections using monoclonal antibodies to 2 distinct proliferation-specific proteins: Ki-67, which is expressed throughout the cell cycle, and a novel cell cycle-associated protein, repp86, the expression of which is restricted to the cell cycle phases S, G2, and M. The ratio of the 2 immunolabeling indices defines the rate of transition through the restriction point. Telomerase activity was detected in 50 of 53 ECs (94%). Its levels correlated significantly with FIGO stage (P =.01) and FIGO grade (P =.003) but not with myometrial invasion. They were weakly associated with the overall proliferative activity (Ki-67, r =.48) but significantly with the repp86 index (r =.64) and even more strongly with the repp86:Ki-67 ratio (r =.77). There was no correlation with mean telomere length. In the group of tumors with high telomerase activity, 5 patients had relapses and 2 died of the disease within a median follow-up period of 29 months. Recurrence showed no relation to FIGO grade and stage. No events were observed in the group with low telomerase activity. In a multivariate model including tumor stage, histopathologic grade, depth of myometrial invasion, and Ki-67 indices, telomerase activity emerged as the only independent predictor of disease progression (P =.0002). It is concluded that beyond a link to proliferation, high telomerase activity reflects a deregulation of the cell cycle associated with an increased rate of cells entering S phase and a higher degree of malignancy. Therefore, quantitative analysis of telomerase activity may be useful for identifying EC patients at high risk for recurrence.
Collapse
Affiliation(s)
- G Bonatz
- Department of Gynecology and Obstetrics, and Department of Pathology and Hematopathology, University of Kiel, Kiel, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Telomeres, the extreme ends of the chromosomes play a key role in the process of cellular aging. Due to the 'end-replication-problem', successive shortening of the telomeres with each cell division results in a mitotic clock and it was shown in vitro that this clock limits the replicative capacity of cell proliferation. Telomerase counteracts telomere erosion and provides some somatic cells an unlimited proliferative potential in vitro. The present views of telomeres and telomerase functions in cellular aging in vitro are presented. Possibilities and limitations in the evaluation of the in vivo impact of telomere erosion on human aging, aging syndromes and age related diseases are reviewed. Unresolved questions, future experimental approaches and emerging therapeutic applications are discussed.
Collapse
Affiliation(s)
- W Klapper
- Institute for Hematopathology, Center for Pathology and Applied Cancer Research, Christian-Albrechts-University Kiel, Niemannsweg 11, D-24105, Kiel, Germany.
| | | | | |
Collapse
|
38
|
Kapur S, Menke MA, Tiemann M, Schubert C, Parwaresch R. Early mycosis fungoides: molecular analysis for its diagnosis and the absence of p53 gene mutations in cases with progression. J Dermatol Sci 2001; 26:36-45. [PMID: 11323219 DOI: 10.1016/s0923-1811(00)00159-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The histological diagnosis of initial mycosis fungoides (MF) and the molecular mechanisms that are responsible for its progression and transformation to the more highly malignant variants of MF remain largely unknown. Because of the rare occurrence of these tumours, the need for snap frozen skin biopsy specimens and the difficulty to obtain suitable material for karyotypic and genotypic analysis, specific cytogenetic and molecular lesions have not yet been identified. In particular the role of known oncogenes and tumour suppressor genes, including the p53 gene, in the pathogenesis and clinical progression of MF has not been extensively investigated. The present study was carried out using the polymerase chain reaction (PCR) technique combined with temperature gradient gel electrophoresis (TGGE) to detect mutations of the p53 gene in 58 patients with MF. TGGE analysis was also used in combination with clonality analysis by means of T-cell receptor gamma (TCRG) gene rearrangement studies to distinguish parapsoriasis en plaque and initial MF from patch/plaque stage MF. More than 83% of the diagnoses of initial MF could be confirmed using PCR-TGGE analysis. However, although the sensitive TGGE analysis was used for all exons, p53 gene polymorphisms were found in 4 and p53 gene mutation in only 1 of 58 biopsy specimens. It appears unlikely that p53 gene mutations play a role in either the pathogenesis of parapsoriasis and initial MF or their progression to advanced stages of MF. However, TCRG gene rearrangement studies by means of TCR-TGGE analysis may be useful for distinguishing histologically discordant cases of initial MF.
Collapse
Affiliation(s)
- S Kapur
- Institute of Pathology (Indian Council of Medical Research), Safdarjung Hospital Campus, 110029, New Delhi, India.
| | | | | | | | | |
Collapse
|
39
|
Xie X, Wacker HH, Huang S, Preuss D, Parwaresch R, Tiemann M, Pfreundschuh M. Identification of targets for immunotherapy of lymphomas. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80531-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Abstract
Replication of eukaryotic linear chromosomes is incomplete and leaves terminal gaps. The evolutionary widely distributed solution to this "end replication" is twofold: chromosome ends are capped with telomeres, bearing multiple copies of redundant telomeric sequences, and the telomerase enzyme can add (lost) telomeric repeats. Telomerase in humans, as in all mammals, is ubiquitous in all embryonic tissues. In adults, telomerase remains active in germs cells, and, although down-regulated in most somatic tissues, telomerase is active in regenerative tissues and notably, in tumor cells. Telomerase activity is linked to cellular proliferation, and its activation seems to be a mandatory step in carcinogenesis. In contrast to mammals, indeterminately growing multicellular organisms, like fish and crustaceae, maintain unlimited growth potential or 'immortality' in all somatic tissues throughout their entire life. Also this cell immortalization is brought about by maintaining telomerase expression. Disease prognosis for human tumors includes evaluation of cell proliferation, based on the detection of proliferation markers with monoclonal antibodies. The significance of the classical marker Ki-67, and of a novel marker repp-86 are compared with semiquantitative telomerase assays. For tumor therapy, telomerase inhibitors are attractive tools. Results with telomerase knock-out mice have revealed promise, but also risk of this approach. On the other side, telomerase stimulation is attractive for expanding the potential of cellular proliferation in vitro, with possible applications for transplantation of in vitro expanded human cells, for immortalizing primary human cells as improved tissue models, and for the isolation of otherwise intractable products, like genuine human monoclonal antibodies.
Collapse
Affiliation(s)
- G Krupp
- Institute for Hematopathology, Center for Pathology and Applied Cancer Research, Christian-Albrechts-University, Kiel, Germany.
| | | | | |
Collapse
|
41
|
Kellner U, Haenssle HA, Rudolph P, Parwaresch R. Detection of four new single-stranded telomeric DNA binding proteins by means of an optimized protein blotting procedure. Pathol Res Pract 2001; 196:801-6. [PMID: 11156320 DOI: 10.1016/s0344-0338(00)80079-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The preservation and replication of telomeres are likely to involve multiple protein interactions. We describe a procedure for detecting sequence-specific telomeric DNA binding proteins in crude nuclear extracts. The technique involves electrophoretic transfer of SDS-PAGE fractionated crude nuclear proteins onto PVDF membranes with subsequent incubation in 2% (wt/vol) bovine serum albumin blocking solution. Incubation of the blocked filters with a 5'-biotin-labeled telomeric DNA probe under optimal binding conditions and subsequent biotin detection by means of peroxidase-linked streptavidin complexes reveals sequence-specific protein-telomeric DNA interactions. Using this technique, we identified 13 proteins that specifically bind the single-stranded telomere repeats of (TTAGGG)n, four of which have not been characterized as telomere binding so far.
Collapse
Affiliation(s)
- U Kellner
- Center of Pathology, University of Kiel, Germany.
| | | | | | | |
Collapse
|
42
|
Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, Parwaresch R. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001; 32:311-9. [PMID: 11274641 DOI: 10.1053/hupa.2001.22748] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Simultaneous overexpression of c-erbB-2 and p53 has been reported to be prognostically unfavorable in breast cancer. Herein, we show that concurrent overexpression of these 2 proteins is associated with a marked reduction in the relative fraction of cells in G(1) phase of the cell cycle, indicating an accelerated cell cycle progression. Using an immunohistochemical approach, we examined 261 cases of node-negative infiltrating ductal carcinomas of the breast with respect to c-erbB-2 and p53 expression and to the proliferative activity measured by the Ki-67 index. By means of a novel monoclonal antibody, Ki-S2, which exclusively recognizes proliferating cells in the S, G(2), and M phases of the reproductive cycle, we were further able to calculate the relative fraction of the cells having passed the restriction point at the G(1)/S boundary, thus defining a cycling ratio (CR). The results were correlated with clinical outcome; median follow-up time was 96 months. Tumors that simultaneously overexpressed c-erbB-2 and p53 had a high median CR and followed an unfavorable course. However, increased CRs were also observed independently of c-erbB-2 and p53 overexpression, suggesting that other molecular mechanisms may contribute to acceleration of cell cycle progression. In a multivariate analysis that included patient age, tumor size, hormone receptor status, c-erbB-2 and p53 expression, and the Ki-67 index, CR emerged as the most significant independent predictor of overall and disease-free survival (P <.0001). It is concluded that the CR is a gauge of cell cycle deregulation and therefore may be a powerful indicator of the biologic behavior of cancers. HUM PATHOL 32:311-319.
Collapse
Affiliation(s)
- P Rudolph
- Department of Pathology, University of Kiel, Kiel, Germany
| | | | | | | | | | | | | |
Collapse
|
43
|
Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H, Parwaresch R. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol 2001; 23:134-8. [PMID: 11216707 DOI: 10.1097/00043426-200102000-00014] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Cerebral involvement of systemic mastocytosis and intracranial sarcoma of myelogenic origin are well known entities. An 8-year-old girl with an isolated cerebral mast cell tumor is presented. Specific histopathologic stains were used to confirm the diagnosis detecting immunophenotype and proliferative activity. Treatment with irradiation, intrathecal cytarabine, and interferon-alpha2b did not induce regression whereas polychemotherapy did. Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location.
Collapse
Affiliation(s)
- P P Guenther
- Department of Pediatrics, Technical University Dresden, Germany.
| | | | | | | | | | | | | |
Collapse
|
44
|
Schubert C, Parwaresch R, Rudolph P. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus. Virchows Arch 2001; 438:166-72. [PMID: 11253119 DOI: 10.1007/s004280000340] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Clinically and histologically, the concept of dysplastic nevi remains controversial. To elaborate more precise criteria for the nevi of patients with dysplastic naevus syndrome (DNS), we examined 58 nevi from seven DNS patients who developed one or several malignant melanomas. Clinical presentation and histomorphology were evaluated, and immunohistochemistry was performed using proliferation marker Ki-S5 and antibody DO-7 to the p53 protein. Sixty nevi from individuals without history of melanoma served as controls. Of the DNS nevi, 21 (36.2%) exhibited no morphological particularities. The remaining 37 nevi presented distinctive histological features consisting of a slight epidermal acanthosis, spitzoid vertically oriented nests of dyscohesive nevus cells, and single-standing atypical melanocytes in the basal cell layer of the epidermis. Immunohistochemical analysis revealed an average proliferation index of 2.5%, which significantly surpassed the mean growth fraction of conventional dysplastic nevi (<1%). No increase in p53 expression was observed. Characteristically, active proliferation was found in junctional single-standing melanocytes with or without nuclear atypia rather than in nest-shaped compounds. In conclusion, certain moles of patients with DNS possess distinctive features. The newly characterized criteria may provide a basis for the diagnosis of DNS and might help to identify patients at increased risk for malignant melanoma by examination of a single biopsy.
Collapse
Affiliation(s)
- C Schubert
- Institute of Dermatology and Dermatopathology, Buchholz, Germany
| | | | | |
Collapse
|
45
|
Menke DM, Horny HP, Griesser H, Tiemann M, Katzmann JA, Kaiserling E, Parwaresch R, Kyle RA. Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol 2001; 115:119-26. [PMID: 11190797 DOI: 10.1309/l2gr-pcfm-g4a3-ghdw] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
To determine whether primary lymph node plasmacytoma (PLNP) is a distinct entity among other types of plasma cell neoplasia, we analyzed a large series of PLNPs from 2 large lymphoma registries to compare histologic, immunophenotypic, and clinical features of PLNPs, nonnodal extramedullary plasmacytomas, and multiple myeloma. Twenty-five PLNPs (clinical data on 15 cases) were compared with 10 non-lymph node plasmacytomas and 51 cases of multiple myeloma; 36 cases of reactive plasmacytoses were used as controls. The histologic features of PLNP and other extramedullary plasmacytomas were similar. The histologic features of PLNPs were more immature than those of reactive plasmacytoses and less immature than in multiple myeloma. The immunophenotype of PLNPs significantly differed from that of reactive plasmacytoses, other extramedullary plasmacytomas, and multiple myeloma. PLNPs did not progress to multiple myeloma, unlike other extramedullary plasmacytomas, even though survival in PLNPs and other extramedullary plasmacytomas was similar. Our findings suggest that PLNPs may be distinct from other plasma cell dyscrasias.
Collapse
Affiliation(s)
- D M Menke
- Department of Pathology, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Miettinen HE, Järvinen TA, Kellner U, Kauraniemi P, Parwaresch R, Rantala I, Kalimo H, Paljärvi L, Isola J, Haapasalo H. High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 2000; 26:504-12. [PMID: 11123716 DOI: 10.1046/j.1365-2990.2000.00282.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The role of molecular markers predicting the prognosis and the selection of patients for further adjuvant therapies is not well established in oligodendroglioma patients. A potential prognostic as well as a therapeutically predictive factor, topoisomerase IIalpha (topoIIalpha), is a molecular target for certain cytotoxic drugs. Its expression has been shown to correlate with the prognosis in a number of different cancers and with the chemosensitivity of cancer cells in vitro. The expression of topoIIalpha was evaluated immunohistochemically in 59 oligodendrogliomas and in 29 mixed gliomas with a predominating oligodendroglioma component by the use of a tissue microarray technique. In the gliomas, the percentage of topoIIalpha immunopositive cells protein expression varied from 0.0 to 49.1% (5.2 +/- 8.3%, mean+/- SD). In oligoastrocytomas, the mean topoIIalpha score was significantly higher in the oligodendroglioma than in the astrocytoma component of the tumour (5.37 +/- 5.58% vs. 1.89 +/- 2.49%, P = 0.018). A significant association was found between the high proportion of topoIIalpha positive cells and high grade of the tumour (P < 0.0001), high tumour proliferation rate (P < 0.0001), p53 overexpression (P = 0.01) and high expression of tumour suppressing retinoblastoma protein (P = 0.023). TopoIIalpha expression was not associated with the age or sex of patient, and the rate of apoptosis. TopoIIalpha expression associated highly significantly with patient prognosis; a significantly higher proportion of patients with low rather than with high topoIIalpha score was alive at the end of the 5-year follow-up (P = 0.03). Cox analysis was used to demonstrate that topoIIalpha had an independent prognostic value for survival (P = 0.034). In conclusion, high topoIIalpha expression characterizes oligodendrogliomas and oligoastrocytomas which are poorly differentiated, have high proliferation rate, and has prognostic value for overall survival of these patients. Therefore, topoIIalpha may be a useful marker for better targeted selection of poor prognosis oligodendroglioma patients for adjuvant therapy.
Collapse
Affiliation(s)
- H E Miettinen
- Department of Pathology, Tampere University Hospital, Tampere,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Topoisomerases constitute a family of highly conserved essential enzymes, which exist in all investigated living pro- and eukaryotic cells. They are indispensable for the control of DNA topology. Humans possess 4 types of topoisomerases, i. e. topoisomerase (topo) I, II, III and V. Topo I, a 100-kDa protein, is a member of the type-I enzyme group (type IB). Functionally, it is an ATP-independent DNA single-strand endonuclease and ligase that functions mainly during transcription but also during DNA replication. Topo II belongs to the type-II enzymes and is represented in humans by 2 highly homologous isoforms, alpha (170 kDa) and beta (180 kDa). Contrary to topo I, the 2 topo II isoforms are ATP-dependent double-strand endonucleases and ligases. Topo I and the beta-form of topo II are expressed in a proliferation-independent manner, whereas topo IIalpha is cell-cycle-regulated. Because of the crucial role of topoisomerases for the maintenance and replication of DNA during proliferation, cells become highly vulnerable when these functions are lost. Consequently, a wide range of drugs with cytostatic effects are topo inhibitors. Topo I inhibitors in clinical use belong to the camptothecin family, e. g. topotecan and irinotecan. Topo IIalpha inhibitors are constituents of most chemotherapeutic protocols and form a large heterogeneous group. It includes clinically used compounds such as the podophyllotoxin analogues etoposide and teniposide, the anthracyclines daunorubicin, doxorubicin and idarubicin, the anthracenedione mitoxantrone and amsacrine. Recently, substances with dual specificity that inhibit both topo I and topo IIalpha have been found. The clinical relevance of these new compounds remains to be established. Specific inhibitors of topo IIbeta have not been described yet. The majority of topo inhibitors interfere with the religation step in the normal action of the enzymes, which leads to a stabilisation of the so-called cleavable complex. This results in DNA single-strand breaks in the case of topo I or double-strand breaks in the case of topo II. DNA single-strand breaks due to topo I inhibition are converted into double-strand breaks in the course of DNA replication. Such topo-mediated DNA strand breaks likely induce repair or apoptosis mechanisms via p53 and/or p21(WAF1/Clip1). As a consequence, while topoisomerases are required for proliferation, proliferation is also essential for efficacious topo inhibition. The cell-cycle-dependent expression of topo IIwas also successfully used for prognostic evaluations of survival in patients with cancer. Copyright 2000 S. Karger GmbH, Freiburg
Collapse
Affiliation(s)
- U. Kellner
- Institut für Pathologie, Otto-von-Guericke-Universität, Magdeburg
| | | | | |
Collapse
|
48
|
Abstract
Ropp 120 (restrictedly overexpressed proliferation-associated protein) is a cytoplasmic protein of 120 kDa that is significantly overexpressed in mitotic cells. Protein sequencing of the immunoaffinity purified 120-kDa protein showed it to be an as yet unknown protein. DNA sequencing revealed a cDNA sequence of 3419 bases, which includes the complete coding region of ropp120 of 2943 bases (981 amino acids). Analysis of the deduced amino acid sequence showed that ropp 120 contains four WD repeats and a well-conserved consensus sequence of serine proteases. The gene encoding ropp120 (HGMW-approved gene symbol C2orf2) was assigned to chromosome 2p21-p22 by means of radiation hybrid and fluorescence in situ hybridization mapping.
Collapse
Affiliation(s)
- H J Heidebrecht
- Department of Hematopathology and Lymph Node Registry, German Association of Pathologists, University of Kiel, Michaelisstrasse 11, Kiel, D-24105, Germany.
| | | | | | | | | |
Collapse
|
49
|
Krams M, Peters J, Boeckel F, Raether A, Ambros PF, Parwaresch R, Harms D. In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing's sarcomas and peripheral primitive neuroectodermal tumors. Virchows Arch 2000; 437:234-40. [PMID: 11037342 DOI: 10.1007/s004280000252] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
It is now widely accepted that the EWS/FLI-1 fusion transcript is associated with tumors of the Ewing family. To test whether it is possible to detect the fusion transcript by means of combining polymerase chain reaction (PCR) methodology and immunohistochemistry, we investigated tumors of the Ewing family using in situ reverse transcriptase (RT)-PCR. We were able to demonstrate the t(11;22) fusion transcript in five of six cases of Ewing's sarcoma and four of four peripheral primitive neuroectodermal tumors. These results were confirmed using fluorescence in situ hybridization in seven tumor samples. In situ RT-PCR-labeled fusion transcripts were found in virtually all tumor cells within a given sample, indicating that each cell possessed the t(11;22) transcript. We conclude from these results that in situ RT-PCR can be used for the rapid detection of EWS/FLI-1 fusion transcripts in biopsy material. The findings also suggest that all cells of the tumors of the Ewing family carry the EWS/FLI-1 fusion transcript.
Collapse
Affiliation(s)
- M Krams
- Department of Pediatric Pathology, University of Kiel, Germany.
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Fluorescence polarization has been used recently to monitor diverse macromolecular interactions. In this report, the application of fluorescence polarization has been extended to monitor ribozyme reactions in real time. With fluorescently labeled substrate RNAs, group I ribozyme ligation and hammerhead ribozyme cleavage reactions were studied by fluorescence polarization in substrate excess (multiple turnover) conditions. These results also show that fluorescently labeled RNAs remain active substrates for ribozymes. Furthermore, a direct comparison of fluorescence polarization with fluorescence resonance energy transfer showed that both techniques were comparable for monitoring ribozyme reactions.
Collapse
Affiliation(s)
- K K Singh
- Institute for Hematopathology, University of Kiel, Germany.
| | | | | | | | | |
Collapse
|